Amarin Pharma Inc. on Tuesday asked the U.S. Supreme Court to decline review of a patent dispute involving generic drug “skinny labels,” arguing that the case centers on fact-specific issues that are not appropriate for high court consideration. Amarin’s filing responds to a brief submitted earlier this month by U.S. Solicitor General D. John Sauer,
Amarin Pharma Inc. on Tuesday asked the U.S. Supreme Court to decline review of a patent dispute involving generic drug “skinny labels,” arguing that the case centers on fact-specific issues that are not appropriate for high court consideration.
Amar… [4020 chars]
Source: USA Herald | Published: 2025-12-25T07:59:44Z
Credit: USA Herald
